Chardan Capital maintains Buy rating on Camp4 Therapeutics, $6 price target
Chardan Capital maintained their Buy rating on Camp4 Therapeutics's stock with a price target of $6.00.The price target implies an upside of 55.8% from the Sep 28 close of $3.85.Key takeaways from the analyst noteStrong Pipeline Potential: Camp4 Therapeutics is focused on developing innovative RNA…